Shenogen Announces a New Member: Dr. Jian Peng


August 5th 2015, Beijing, China


ShenogenPharma Group announces a new member Dr. Jian Peng to management team. Dr. Peng is Senior Vice President, responsible for regulatory affairs and drug development strategy.


“Dr. Peng has significant impact on oncology drugs regulatory and clinical research in China. His joining will dramatically expedite regulatory process of clinical product as well as company development. Welcome to Shenogen family!” said Dr. Meng, CEO of ShenogenPharma Group.


Dr. Peng has high reputation in drug regulatory and drug development,and has worked in the field for the last 20 years. Prior to joining Shenogen, he served as scientific advisor, director of clinical research & oncology head of Asia Pacific, Sanofi, sequentially. Before that, Dr. Peng was in charge of oncology drug approval in Center of Drug Evaluation (CDE), Chinese Food and Drug Administration (CFDA). He waslead director of the program for oncology drug clinical research and evaluation, which helped to improve quality of clinical trials in China. Dr. Peng played a key role in leading several Chinese first-in-class oncology drugs to approval, including Icotinib from BettaPharma, Apatinib from Heng Rui Medicine, Chidamide from Chipscreen. He was also the leader of Oxaliplatin (Sanofi) clinical trials and regulatory process in China. Dr. Peng got his PhD degree from China Pharmaceutical University and master degree from China Academy of Chinese Medicine Sciences. Dr. Peng is author/co-author of more than 20 SCI papers and serves as a member of Chinese Society of Clinical Oncology (CSCO).



About Shenogen

ShenogenPharma Group is a drug discovery and development company based in Beijing, China, that dedicated the development of first-in-class therapeutics for cancer treatment. We possess robust intellectual property rights around a novel membrane-bound estrogen receptor, ER-alpha 36, which is related to tumor metastasis. Under the motto of “Better Medicine, Better Life” and a seasoned management team, together with our partners, Shenogen has developed an impressive product pipeline. Our pipeline consists of novel small molecule and antibody therapeutics for cancer treatment which includes liver cancer, breast cancer, other solid tumors and leukemia. Our lead molecule, icaritin, is completingPh II clinical trial for treatment of advanced hepatocellular carcinoma.

(For more information, please visit



Shenogen Announces a New Member: Dr. Jian Peng